This month, 23andMe introduced a new health report category, Pharmacogenetics, that includes the following reports: CYP2C19 Drug Metabolism, DPYD Drug Metabolism, SLCO1B1 Drug Transport.*
These reports were released to a subset of eligible 23andMe subscription service customers who have opted-in to receive health reports. From the reports, customers can learn whether they have specific genetic variants that may influence how their body processes certain medications.
Available now, is an on-demand walkthrough of our Pharmacogenetics reports. By watching this recording, you will learn about our Pharmacogenetics report category, get an overview of all three reports, a walkthrough of the CYP2C19 Drug Metabolism report, and learn about resources available for healthcare professionals, including our new Pharmacogenetics Portal for Healthcare Professionals.
View sample reports for DPYD Drug Metabolism “likely normal metabolizer” and CYP2C19 Drug Metabolism “likely poor metabolizer.”
You can also view sample reports for the different Pharmacogenetics reports and report outcomes located under the reports tab on our Healthcare Professionals site.
This report walkthrough is intended for healthcare professionals.
Cindy Kosinski is a Product Scientist at 23andMe where she evaluates the scientific literature and develops content for the 23andMe health product. She played a key role in the FDA authorization of the 23andMe Pharmacogenetics reports and helped develop these reports as well as other health reports and features. Cindy earned a PhD in Pharmaceutical Sciences and Pharmacogenomics from the University of California, San Francisco.
*The 23andMe PGS test uses qualitative genotyping to detect 6 variants in 3 genes in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic and does not describe the association between detected variants and any specific therapeutic. Results should be confirmed in a clinical setting with independent genetic testing before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For a complete list of the 6 variants tested, visit https://permalinks.23andme.com/pdf/pgt_product_info_page_21jan2020.pdf.